AcuCort gives an update on the continued work concerning the bioequivalence study for US registration
AcuCort AB (Spotlight Stock Market: ACUC) gives further information on the results from the second bioequivalence study for a US registration, and reports on the efforts to establish the causes of non-achieved bioequivalence and to develop options for the continued work with registration and commercialization of the company’s drug candidate ISICORT®.AcuCort has previously reported positive results from the first of the two studies for registration in the US, and from the bioequivalence study on which the company’s submitted application for marketing authorization in Sweden is based. The